{
    "nct_id": "NCT06340711",
    "official_title": "Phase II Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Immunotherapy Refractory Esophagogastric Adenocarcinoma",
    "inclusion_criteria": "* Histologically or cytologically confirmed advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma amenable to intra-tumoral injection (i.e. at least 1 cm in size)\n* Tumor must be PD-L1 positive as defined by a combined positive score (CPS), i.e. CPS ≥ 1 by approved, commercial diagnostic assay\n* Tumor must be HER2 negative as determined by a CLIA-approved laboratory\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 3 weeks of study Day 1.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid)\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (greater than equivalent of 20 mg/day) or any other form of immunosuppressive therapy within 7 days prior to study Day 1.\n* Has known active central nervous system metastases and/or carcinomatous meningitis.\n* Has had prior anti-cancer monoclonal antibody chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1, who has not recovered from adverse events due to a previously administered agent.\n* Has a known additional malignancy within 3 years before the first OBP-301 administration that is progressing or requires active treatment, with the exception of prostate cancer controlled with androgen deprivation therapy.\n* Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n* Is known to have acute or chronic active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)\n* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Has an active infection requiring systemic therapy within 2 weeks of Day 1.\n* Is unable to comply with protocol procedures\n* Previous severe hypersensitivity (≥ Grade 3) to any monoclonal antibody\n* Has not adequately recovered from major surgery or has ongoing surgical complications.\n* Has had an allogenic tissue/solid organ transplant\n* Has certain uncontrolled illnesses\n* Is pregnant or breastfeeding or planning to become pregnant or start breast feeding during the study time period\n* Is expecting to get someone else pregnant during the study time period",
    "miscellaneous_criteria": ""
}